Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quinoxaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.40 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.39 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.38 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoxaline SCHEMBL27507035 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL29612255 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL27705598 | 0.97 | ALDH1A1 (0.52) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL27863276 | 0.97 | ALDH1A1 (0.52) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL6928518 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL5315 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL30320908 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL29355228 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL4000710 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL19877228 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957138-A | Quinoxaline asymmetric hydrogenation method | 哈尔滨工业大学（深圳） | 2022-08-30 | — | — | CN | claimed |
| CN-109962289-B | Electrolyte composition and metal ion battery comprising same | 财团法人工业技术研究院 | 2022-03-11 | — | — | CN | claimed |
| US-10587009-B2 | Electrolyte composition and metal-ion battery employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-03-10 | — | — | US | claimed |
| US-10367227-B2 | Electrolyte composition and metal-ion battery employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-07-30 | — | — | US | claimed |
| US-20190198929-A1 | ELECTROLYTE COMPOSITION AND METAL-ION BATTERY EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-06-27 | — | — | US | claimed |
| US-20180219257-A1 | ALUMINUM-ION BATTERY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-08-02 | — | — | US | claimed |
| CN-106336415-B | A kind of 1,2,4- triazole derivatives of chloride benzopyrazines structure and its preparation method and application | 浙江工业大学 | 2018-05-29 | — | — | CN | claimed |
| US-20170358815-A1 | ELECTROLYTE COMPOSITION AND METAL-ION BATTERY EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-12-14 | — | — | US | claimed |
| CN-106336415-A | 1,2,4-triazole derivative containing chlorobenzopyrazine structure and preparation method and application thereof | 浙江工业大学 | 2017-01-18 | — | — | CN | claimed |
| CN-106243048-A | A kind of hydrazone compounds of chloride benzopyrazines structure and preparation method and application | 浙江工业大学 | 2016-12-21 | — | — | CN | claimed |
| CN-106220633-A | 1,2,4 triazole derivatives of a kind of chloride benzopyrazines structure are as the application of antibacterial | 浙江工业大学 | 2016-12-14 | — | — | CN | claimed |
| CN-106172418-A | The hydrazone compounds of a kind of chloride benzopyrazines structure is as the application of antibacterial | 浙江工业大学 | 2016-12-07 | — | — | CN | claimed |
| CN-1285834-A | Fused pyrazine compound | ONO PHARMACEUTICAL CO (JP) | 2001-02-28 | — | — | CN | claimed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-114957138-A | Quinoxaline asymmetric hydrogenation method | 哈尔滨工业大学（深圳） | 2022-08-30 | — | — | CN | disclosed |
| CN-1342151-A | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1286683-A | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA (JP) | 2001-03-07 | — | — | CN | disclosed |
| CN-1285834-A | Fused pyrazine compound | ONO PHARMACEUTICAL CO (JP) | 2001-02-28 | — | — | CN | disclosed |
| US-4973736-A | Diethers of m- or p-hydroxyphenol | BASF AKTIENGESELLSCHAFT (DE) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | CCR5 531/4885HTR1A 1658/4885ADRA1D 289/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | CCR5 4446/4885HTR1A 406/4885ADRA1D 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.